These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 6128656)

  • 1. Selectivity of dynorphin for kappa opioid receptors.
    James IF; Chavkin C; Goldstein A
    Life Sci; 1982 Sep 20-27; 31(12-13):1331-4. PubMed ID: 6128656
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of dynorphin-selective Kappa receptors in mouse vas deferens and guinea pig ileum. Spare receptor fraction as a determinant of potency.
    Cox BM; Chavkin C
    Mol Pharmacol; 1983 Jan; 23(1):36-43. PubMed ID: 6135144
    [No Abstract]   [Full Text] [Related]  

  • 3. Opioid receptors and acetaminophen (paracetamol).
    Raffa RB; Walker EA; Sterious SN
    Eur J Pharmacol; 2004 Oct; 503(1-3):209-10. PubMed ID: 15496316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Demonstration of a specific dynorphin receptor in guinea pig ileum myenteric plexus.
    Chavkin C; Goldstein A
    Nature; 1981 Jun; 291(5816):591-3. PubMed ID: 6264311
    [No Abstract]   [Full Text] [Related]  

  • 5. Selective inactivation of opioid receptors in rat hippocampus demonstrates that dynorphin-A and -B may act on mu-receptors in the CA1 region.
    Chavkin C; Henriksen SJ; Siggins GR; Bloom FE
    Brain Res; 1985 Apr; 331(2):366-70. PubMed ID: 2859095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynorphin interaction at the kappa-opiate site.
    Huidobro-Toro JP; Yoshimura K; Lee NM; Loh HH; Way EL
    Eur J Pharmacol; 1981 Jun; 72(2-3):265-6. PubMed ID: 6113976
    [No Abstract]   [Full Text] [Related]  

  • 7. Kappa opiate receptors inhibit release of oxytocin from the magnocellular system during dehydration.
    Summy-Long JY; Rosella-Dampman LM; McLemore GL; Koehler E
    Neuroendocrinology; 1990 Apr; 51(4):376-84. PubMed ID: 1971712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roles of endogenous opioid peptides in modulation of nocifensive response to formalin.
    Wu HE; Hung KC; Mizoguchi H; Nagase H; Tseng LF
    J Pharmacol Exp Ther; 2002 Feb; 300(2):647-54. PubMed ID: 11805228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence that dynorphin-(1-13) acts as an agonist on opioid kappa-receptors.
    Oka T; Negishi K; Suda M; Sawa A; Fujino M; Wakimasu M
    Eur J Pharmacol; 1982 Jan; 77(2-3):137-41. PubMed ID: 6277659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation of brain membranes containing a single type of opioid receptor highly selective for dynorphin.
    James IF; Chavkin C; Goldstein A
    Proc Natl Acad Sci U S A; 1982 Dec; 79(23):7570-4. PubMed ID: 6130527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of the receptor selectivity of opioid agonists in the guinea-pig ileum and mouse vas deferens by use of beta-funaltrexamine.
    Hayes AG; Sheehan MJ; Tyers MB
    Br J Pharmacol; 1985 Dec; 86(4):899-904. PubMed ID: 3000501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynorphin A(1-17)-induced feeding: pharmacological characterization using selective opioid antagonists and antisense probes in rats.
    Silva RM; Grossman HC; Hadjimarkou MM; Rossi GC; Pasternak GW; Bodnar RJ
    J Pharmacol Exp Ther; 2002 May; 301(2):513-8. PubMed ID: 11961051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [3H] dynorphin binding to guinea pig and rat brain.
    Young E; Walker JM; Houghten R; Akil H
    Life Sci; 1983; 33 Suppl 1():287-90. PubMed ID: 6141490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of an irreversible opiate antagonist (beta-FNA, beta-funal-trexamine) to demonstrate dynorphin selectivity for K-opioid sites.
    Huidobro-Toro JP; Yoshimura K; Way EL
    Life Sci; 1982 Nov; 31(22):2409-16. PubMed ID: 6130451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [3H]dynorphin A binding and kappa selectivity of prodynorphin peptides in rat, guinea-pig and monkey brain.
    Young EA; Walker JM; Lewis ME; Houghten RA; Woods JH; Akil H
    Eur J Pharmacol; 1986 Mar; 121(3):355-65. PubMed ID: 2870933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid receptor selectivity of dynorphin gene products.
    James IF; Fischli W; Goldstein A
    J Pharmacol Exp Ther; 1984 Jan; 228(1):88-93. PubMed ID: 6141278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions.
    Kreek MJ; Schluger J; Borg L; Gunduz M; Ho A
    J Pharmacol Exp Ther; 1999 Jan; 288(1):260-9. PubMed ID: 9862779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereostructure-activity relationship of opioid agonist and antagonist bivalent ligands. Evidence for bridging between vicinal opioid receptors.
    Portoghese PS; Larson DL; Yim CB; Sayre LM; Ronsisvalle G; Lipkowski AW; Takemori AE; Rice KC; Tam SW
    J Med Chem; 1985 Sep; 28(9):1140-1. PubMed ID: 2993609
    [No Abstract]   [Full Text] [Related]  

  • 19. N,N-diallylated analogs of dynorphin A-(1-13) as potent antagonists for the endogenous peptide and selective kappa opioid analgesics.
    Lemaire S; Parent P; Lapierre C; Michelot R
    Prog Clin Biol Res; 1990; 328():45-8. PubMed ID: 1968273
    [No Abstract]   [Full Text] [Related]  

  • 20. Involvement of spinal kappa opioid receptors in the antagonistic effect of dynorphins on morphine antinociception.
    Song ZH; Takemori AE
    Life Sci; 1991; 48(15):1447-53. PubMed ID: 1672725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.